We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fewer patients treated with rifaximin had an overt ...
Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy. HealthDay News — For patients with a history of overt hepatic ...
Over 6 months, 23.2% of patients receiving rifaximin monotherapy experienced an OHE breakthrough episode compared with 49% of patients receiving lactulose monotherapy (P<0.0001), reported Jasmohan S.
“RFX [rifaximin] therapy is effective and well-tolerated in preventing HE and can be used as the first choice in the prophylaxis of HE after TIPSS,” the authors wrote. This study was led by Yangyang ...
Please provide your email address to receive an email when new articles are posted on . Rifaximin retention decreased with time, with rates of 42% at 180 days dropping to 16% by 540 days. High cost, ...
Researchers conducted a cohort analysis using data from electronic medical records (March 2010 to May 2023) across seven hospitals in the Netherlands to investigate the effect of rifaximin-alpha on ...
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
Bausch Health’s gastroenterology business arm, Salix, is using its new spot for Xifaxan to educate patients with cirrhosis of the liver about the risk of overt hepatic encephalopathy (OHE). Up to 80% ...
LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback